MCHRI enters partnership with Menarini Biomarkers

The two will create a regional and international hub for non-invasive diagnostics in Singapore.

SingHealth Duke-NUS' Maternal and Child Health Research Institute (MCHRI) signed a three-year memorandum of understanding with Menarini Biomarkers Singapore during the MCHRI launch at KK Women's and Children's Hospital on 8 October. 

"MBS is delighted to partner with MCHRI for this research and development project in Singapore, the first such partnership we have established outside the European Union," said director Maurizio Luongo. "The CB-NIPD process has the immense potential for broad-based applications and can be a key tool for precision medicine applications, in particular in oncology. We look forward to harnessing the strengths of both MCHRI and Menarini through this valuable partnership."

MCHRI and MBS will pioneer clinical trials using cell-based, non-invasive prenatal diagnosis. The process will use Menarini proprietary technology, which is non-invasive and carries minimal risk to the pregnant woman.